Want to see CBLL full AI Analyst Report?
EarningsQ2 2026 Earnings Report
CBLL Q2 2026 EPS Results
Actual EPS-$0.51
Consensus EPS-$0.47
Beat/MissMissed by -$0.04
One Year Ago EPS-$0.38
CBLL Q2 2026 Revenue Results
Actual Revenue$28.10M
Expected Revenue$27.28M
Beat/MissBeat by +$821.00K
YoY Revenue Growth+32.54%
Earnings Announcement Details
QuarterQ2 2026
Date08/10/2026
TimeAfter Close
Conference CallMonday, August 10, 2026
CBLL Upcoming Earnings
Ceribell, Inc.'s next earnings date is estimated for November 17, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
CBLL Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call showcased strong top-line growth, high gross margins, meaningful regulatory clearances, expanding product portfolio (neonate/pediatric/delirium), and favorable reimbursement (NTAP), supported by a solid cash position and improved guidance — all material positive developments. Offsetting these positives are widening GAAP losses, materially higher operating expenses (including stock-based comp and litigation costs), continued negative adjusted EBITDA, and timing uncertainty for revenue contributions from new product initiatives. On balance, the company appears to be executing commercial and technical milestones that should drive future growth, while actively reinvesting and accepting near-term profitability pressure.Company Guidance
Strong Revenue Growth
Total revenue of $28.1M in Q2 2026, up 33% year-over-year (from $21.2M) and up 6% sequentially quarter-over-quarter, driven by same-store growth and increased adoption across new and existing accounts.
Product and Subscription Revenue Expansion
Product revenue $21.2M (+33% YoY from $15.9M); subscription revenue $6.9M (+30% YoY from $5.3M), reflecting balanced growth across hardware and recurring software/services.
Account Base Growth and Commercial Momentum
Active account base increased to 712 hospitals, +32 accounts in the quarter; continued commercial investment (account acquisition and strategic account management) supporting an accelerating pipeline at the system level.
Record High Gross Margin
Reported gross margin of 92% in Q2 2026 (vs. 88% prior year). Excluding a $1.6M tariff refund (recognized $1.0M in COGS and $0.6M to inventory), gross margin was 89%, with the company expecting to sustain high-80s margins for 2026 due to manufacturing optimization (Vietnam) and cost initiatives.
Regulatory Clearances and Product Momentum
Multiple FDA 510(k) clearances announced: two new algorithms (artifact rejection and epileptiform abnormality), recorder enhancements (video/ECG, ability to integrate other vital signs, continuous plugged-in monitoring), and two headband designs enabling longer continuous monitoring and optional full montage capability — all expanding clinical utility and TAM.
Delirium Milestones and Reimbursement
Delirium monitoring solution received 510(k) clearance (previous) and a favorable CMS final rule establishing an NTAP effective Oct 1, 2026 providing up to $2,170 incremental reimbursement per qualified patient; commercial pilot live in multiple sites with positive early clinical/operational feedback.
Clinical Evidence Strengthening Value Proposition
High-impact study published in Critical Care Medicine showing Clarity-detected seizure burden correlates with worse outcomes: patients with detected seizure burden were ~3.6x more likely to experience severe disability or death at discharge, and each additional hour of detected seizure activity was associated with nearly a 2x increase in that risk — supporting clinical imperative for use.
Balance Sheet and Financing Flexibility
Cash, cash equivalents, and marketable securities of $129M as of 06/30/2026; successfully refinanced credit facility with access up to $60M committed plus $25M uncommitted, extending repayment profile and expected to reduce interest expense beginning in Q4.
Raised 2026 Revenue Guidance
Updated full-year 2026 revenue guidance to $114M–$117M (previously $112M–$116M), implying annual growth of approximately 28%–31% over 2025, reflecting momentum from new account additions and same-store utilization gains.
Improved Adjusted EBITDA Trend
Adjusted EBITDA loss of $9.8M in Q2 2026 vs. $10.0M in Q2 2025, indicating modest improvement in operating performance when excluding non-cash stock-based compensation and litigation-related expenses.
CBLL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed